- IBM Corp., the health insurer WellPoint Inc. and MSKCC announced two Watson-based applications – one to help diagnose and treat lung cancer and one to help manage health insurance decisions and claims.
- A press release announced that researchers at MSKCC have treated the first patient with a new experimental vaccinia virus-based cancer therapy designed for patients with malignant pleural mesothelioma or non-small cell lung cancer.
- Peter Bach of MSKCC is quoted in a Nature News article about the impact of the economic downturn on US academic medical campuses like the University of California, San Francisco (UCSF).
Category Archives: MSK in the News
MSKCC in the News: January 10 – January 23
- Xconomy.com recently chronicled MSKCC’s expanding efforts in developing medical device technologies.
- An article on the development of the PapGene test for cervical, endometrial and ovarian cancer – by researchers at Johns Hopkins University, MSKCC, and the University of Sao Paolo in Brazil – was published in the journal Science Translational Medicine.
MSKCC in the News: December 26 – January 9
- Lorus Therapeutics Inc. announced that its Phase I clinical study, conducted at MSKCC and the MD Anderson Cancer Center, of LOR-253 has successfully escalated to the target dose level based on predicted and observed clinical effects without limitation by toxicity.
- MSKCC’s Dr. Peter Bach was quoted in a Reuters article about a study that found that pediatricians-in-training are more likely to plan to go into primary care – rather than a specialty field – if they have lots of debt from college and medical school.
- MSKCC was featured in Health Magazine’s top 12 medical breakthroughs of 2012.